首页> 外国专利> Antiarthritic and antirheumatic medicaments - contg. (1)-ribofuranosyl (1,2,4)-triazole (3)-carboxamide derivs.

Antiarthritic and antirheumatic medicaments - contg. (1)-ribofuranosyl (1,2,4)-triazole (3)-carboxamide derivs.

机译:抗关节炎和抗风湿药-续(1)-呋喃呋喃糖基(1,2,4)-三唑(3)-羧酰胺衍生物。

摘要

The medicaments contain furanosyltraizole cpds. of formula (I):- In this formula, R1, R2 and R3, are H, acyl (pref. acetyl or propionyl), or phosphoric acid residues the further acidic functions of which may be presents in salt form and/or esterified in such a way that R1+R2 or R2 +R3 forms a phosphate residue. (I) exert a genuine antiarthritic or antirheumatic effect and can be used in the treatment of arthrtitis or rheumatic disorders when the known agents (which ameliorate symptome only cannot be administered or are ineffective. In the chromic adjuvant arthritis test, (I; R1=R2-R3=H) is active when administered in a dosage of 55mg/kg p.o. twice daily. The pred. cpd. (I) is 1-(beta-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide. Dosage units pref. contain 100-250 mg (I).
机译:药物包含呋喃糖基三唑cpds。在该式中,R 1,R 2和R 3是H,酰基(优选乙酰基或丙酰基)或磷酸残基,其进一步的酸性官能团可以以盐的形式存在和/或被酯化。 R1 + R2或R2 + R3形成磷酸酯残基的方式。 (I)发挥真正的抗关节炎或抗风湿作用,当已知药物(仅能改善症状的药物或不能有效使用时,可用于关节炎或风湿病的治疗)。每天两次以55mg / kg的剂量口服时,R2-R3 = H)有活性。cpd。(I)为1-(β-D-呋喃呋喃糖基)-1,2,4-三唑-3-甲酰胺的剂量单位优选为100-250 mg(I)。

著录项

  • 公开/公告号FR2319331A1

    专利类型

  • 公开/公告日1977-02-25

    原文格式PDF

  • 申请/专利权人 MUCKTER HEINRICH;

    申请/专利号FR19760023195

  • 发明设计人

    申请日1976-07-29

  • 分类号A61K31/00;C07D249/10;C07H19/04;

  • 国家 FR

  • 入库时间 2022-08-22 23:49:00

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号